Why is "ALT-803" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-08 15:28:52
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Interleukin-15 (IL-15) is a protein that in humans is encoded by the IL15 gene. IL-15 is an inflammatory cytokine with structural similarity to Interleukin-2 (IL-2). Like IL-2, IL-15 binds to and signals through a complex composed of IL-2/IL-15 receptor beta chain (CD122) and the common gamma chain. IL-15 is secreted by mononuclear phagocytes following infection by virus(es). This cytokine induces the proliferation of natural killer cells, i.e. cells of the innate immune system whose principal role is to kill virally infected cells.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Nogapendekin Alfa Inbakicept Plus BCG Gains European Approval in BCG-Unresponsive NMIBC With CIS - OncLive
-
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept - Urology Times
-
ALT-803 + Nivolumab Found Safe, Effective in Metastatic NSCLC - Cleveland Clinic
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial - The Lancet
-
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ - Targeted Oncology
-
ANKTIVA FDA Approval: First-in-Class IL-15 Agonist for NMIBC - ImmunityBio
-
Editorial: Modulating cytokines as treatment for autoimmune diseases and cancer: volume II - Frontiers
-
Study treatment schema. - PLOS
-
Clinical Trial Explores Effectiveness of New Treatment for Bladder Cancer Patients - University of Miami
-
New immunotherapy for lung cancer shows promise of success - Medical Xpress
-
FDA approves nogapendekin alfa inbakicept plus BCG for NMIBC - Urology Times
-
N-803 Plus BCG Shows Encouraging Responses in NMIBC - Targeted Oncology
-
Immunotherapy for Glioblastoma - Glioblastoma Cancer Clinical Trial - ImmunityBio
-
IL-15 in the Combination Immunotherapy of Cancer - Frontiers
-
FDA approval sought for Anktiva in papillary NMIBC - Urology Times
-
FDA Accepts BLA Resubmission of N-803/BCG for NMIBC - Targeted Oncology
-
Research progress of interleukin-15 in cancer immunotherapy - Frontiers
-
Anktiva under review in EU for BCG-unresponsive NMIBC with CIS - Urology Times
-
The advantages of NK cell vaccines in solid carcinoma clinical trials: conducted by various biology strategy and technology - Frontiers
-
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities - Frontiers
-
The role of interleukin-15 in the development and treatment of hematological malignancies - Frontiers
-
A NK Cell Odyssey: From Bench to Therapeutics Against Hematological Malignancies - Frontiers
-
Superagonists Pull IL-15 Into Focus in Oncology Care - OncLive
-
Novel Combination Therapies for the Treatment of Bladder Cancer - Frontiers
-
NK Cell–Targeting Strategies Come Into Their Own - OncLive
-
Targeting NK Cells for HIV-1 Treatment and Reservoir Clearance - Frontiers
-
Nogapendekin Alfa Inbakicept Plus BCG Yields Significant DOR in BCG-Naive NMIBC - OncLive
-
Reduction of the HIV-1 reservoir in T cells from people with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells - ASM Journals
-
QUILT 3.032 trial: Anktiva achieves high response rate in BCG-unresponsive NMIBC - Urology Times
-
Mānoa: UH Cancer Center clinical trial could lead to new bladder cancer drug - University of Hawaiʻi at Mānoa
-
Anktiva targets expanded indication in US and global approvals in EU and UK - Urology Times
-
Gene Therapy for NMIBC: A New Era of Treatment - Colin Dinney - UroToday
-
MUSC launches first clinical trial involving two powerful drugs for lung cancer - EurekAlert!
-
Radiotherapy in Combination With Cytokine Treatment - Frontiers
-
Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics - Frontiers
-
Husband, wife face respective cancer diagnoses with thanksgiving, humor - The Medical University of South Carolina
-
Nogapendekin Alfa Inbakicept Plus BCG Maintains CR Rate in BCG-Unresponsive NMIBC With CIS - OncLive
-
Transforming cancer treatment with next-generation cytokines - News-Medical
-
FDA Issues Complete Response Letter to BLA for N-803 in BCG-unresponsive NMIBC in Situ - OncLive
-
Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors - Frontiers
-
CMS issues permanent reimbursement code for Anktiva - Urology Times
-
Anktiva under review in UK for BCG-unresponsive NMIBC with CIS - Urology Times
-
The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy - Frontiers
-
EMA Recommends Approval of Nogapendekin Alfa Inbakicept Plus BCG for NMIBC With CIS - OncLive
-
The B-Cell Follicle in HIV Infection: Barrier to a Cure - Frontiers
-
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells - springermedizin.de
-
Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial - Fierce Biotech
-
FDA Issues Refusal to File for ImmunityBio’s sBLA for Anktiva in BCG-Unresponsive NMIBC - Pharmaceutical Executive
-
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
-
Acute Myeloid Leukemia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 200+ Companies Working in the Domain - PR Newswire
-
ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials - BioSpace
-
Alex Trebek, Harry Reid and Their Pancreatic Cancer Treatment - MedPage Today
-
Despite 'looting' claims, Soon-Shiong’s NantCell to buy Altor - Fierce Biotech
-
Sobita Gautam maintains lead in Chitwan-3, Renu Dahal trails by 803 votes - myRepublica
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.